CompletedPhase IInterventional

Phase I Trial: Quotient Code QSC301409

This is a very early study, known as Phase I, for a new treatment called Quotient Code QSC301409. The main goal of this type of study is to check if a new treatment is safe and to understand how it works in the body. At this stage, the full details about what is being tested and who can take part aren't available yet. These details will be shared publicly within 30 months after the study has finished. Importantly, this study is currently looking for men between the ages of 30 and 65 years old. Further information will be provided once it becomes available to help people understand if this study might be right for them.

At a glance

Status

Completed

Phase

Phase I

Sponsor

Shionogi B.V.

Enrolment target

Start

05 Sep 2025

Estimated completion

15 Oct 2025

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

What is this study about?

This study, called Quotient Code QSC301409, is what’s known as a ‘Phase I’ trial. Clinical trials usually happen in stages. Phase I is the very first step where a new treatment is tried in people, often healthy volunteers or a small group of patients, for the first time. The main aim of this stage is to check if the treatment is safe and to find the right dose. It's not usually about seeing if the treatment works for a particular illness yet.

At the moment, specific details about what this study is investigating are not being openly shared. This is common in the very early stages of research, sometimes to protect new ideas or pending discoveries. However, all studies must eventually share their findings. For this particular study, the full story and results will be made public within 30 months after the study has officially come to an end.

Once the full details are released, they will help patients, doctors, and the public understand exactly what the study found and what it means for future treatments. This approach ensures that everything is eventually transparent, contributing to medical knowledge and progress in a measured way.

Key takeaways

This is an early (Phase I) study for a new treatment.
Full study details will be released within 30 months after the study ends.
The study is currently enrolling men aged 30 to 65 years.
The main goal of a Phase I study is to check for safety and find the right dose.
Specifics about what taking part involves are not yet public.
You have the right to withdraw from any study at any time.

Who may be eligible?

To be part of this early Phase I study, you must be a man between 30 and 65 years old. Beyond these basics, we don't have further details yet on who can or cannot join the study.

As more information becomes available, it will describe other health conditions, medications, or lifestyle factors that might mean someone can or cannot participate. These rules protect the safety of the people taking part and help make sure the study results are clear and reliable.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you a man?
Are you between 30 and 65 years old?
Are you willing to wait for more details on other requirements?
Are you interested in participating in early-stage research?

Answer every question to see your result.

What does participation involve?

Since this is an early-stage study and the full details are not yet available, we don't have information about what taking part would involve. Generally, in Phase I studies, participants might:

* **Have several visits:** This could include initial screening, receiving the study treatment, and follow-up appointments. * **Undergo various assessments:** Such as blood tests, physical exams, and possibly scans, to check how the treatment affects their body. * **Receive a study drug:** This will be a new treatment never used widely before. * **Have regular follow-up:** To monitor their health and any effects of the treatment.

The exact duration of participation and number of visits will be specified once more details are released. It’s always important to fully understand what's required before agreeing to participate in any study.

Potential risks and benefits

Because this is a very early study and the detailed information is not yet public, we don't have specifics on potential benefits or risks. In Phase I studies, the main 'benefit' is often the chance to contribute to medical science and help others in the future by testing new treatments. However, there might also be unknown risks, as it's the first time a new treatment is being given to people. Any potential benefits or risks would be fully explained by the study team, and you would always have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Quotient Sciences Limited
City only
Nottingham, United Kingdom

Common questions

What is a Phase I trial?

It's the very first stage where a new treatment is tested in people, mainly to check if it's safe and to find the right dose.

Why aren't all the details available now?

Sometimes, in early research, details are kept private to protect new ideas. All information will be shared within 30 months after the study ends.

Who can take part in this study?

Currently, it's for men aged between 30 and 65 years old. More specific requirements will be known later.

Will I get the new treatment if I join?

If you meet the requirements and are selected, you would receive the new study treatment, as this is the purpose of the trial.

What happens after the study finishes?

All the findings and details will be made public within 30 months after the study closes, helping advance medical knowledge.

How to find out more

Regulatory Affairs Department

regulatory.affairs@shionogi.eu +44 (0)20 3053 4200 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.